<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01032122</url>
  </required_header>
  <id_info>
    <org_study_id>MIMM1</org_study_id>
    <nct_id>NCT01032122</nct_id>
  </id_info>
  <brief_title>Rituximab in Metastatic Melanoma</brief_title>
  <official_title>Efficacy and Safety of Rituximab, an Anti-CD20 (Cluster of Differentiation Antigen 20) Therapeutic Agent, in Metastatic Melanoma: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether rituximab as an adjuvant therapy in
      clinical stage IIIc / IV (no evidence of disease, AJCC (American Joint Committee on Cancer)
      2002) melanoma patients is safe and prolongs overall survival and disease-free interval.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the only reason is that recruitment was not sufficient to meet the planned patient numbers,
    because complete remissions are still infrequent.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free interval</measure>
    <time_frame>42 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>42 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.</description>
    <arm_group_label>rituximab</arm_group_label>
    <other_name>mabthera</other_name>
    <other_name>rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically verified non-ocular melanoma stage IIIc/IV, no evidence of disease

        Exclusion Criteria:

          -  ECOG (Eastern Cooperative Oncology Group) performance status &gt; 2

          -  Ocular melanoma

          -  Immunodeficiency syndromes or hypogammaglobulinaemia

          -  Active autoimmune diseases

          -  Treatment with immunosuppressive agents other than steroids

          -  Depressed bone marrow function (Leukopenia &lt;3000, platelet count &lt;100.000)

          -  Cardiac insufficiency NYHA (New York Heart Association) IV

          -  active Hepatitis B,C, or HIV infection

          -  Pregnancy or lactation

          -  Interstitial pulmonary disease

          -  Former treatment with anti-CD20 antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Wagner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med Univ Vienna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alice Pinc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Univ Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital Vienna, Dep. of Dermatology, Division of Immunology and Infectious Diseases</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2009</study_first_submitted>
  <study_first_submitted_qc>December 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2009</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Stephan N. Wagner, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>rituximab</keyword>
  <keyword>metastatic</keyword>
  <keyword>stage IIIc/IV</keyword>
  <keyword>stem cell</keyword>
  <keyword>overall survival</keyword>
  <keyword>disease free interval</keyword>
  <keyword>anti-CD20 therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

